Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

27.51 +0.34 (+1.25%)
Streaming Delayed Price Updated: 11:37 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma Plc Cl A

< Previous 1 2 3 4 5 6 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Upgrades 
Via Benzinga
Expedia And 3 Other Stocks Insiders Are Selling
Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Hopeful Golden Cross Forms On Royalty Pharma's Chart
If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%... 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital... 
Via Benzinga
DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger
Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. 
Via InvestorPlace
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market... 
Via Benzinga
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: 
Via Benzinga
BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals... 
Via Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. 
Via InvestorPlace
36 Stocks Moving in Tuesday's Pre-Market Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript
RPRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
Upgrades For Preferred Bank (NASDAQ: 
Via Benzinga
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of... 
Via Benzinga
Cramer Gives His Opinion On Applied Materials, Coinbase And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter. People who were selling the stock didn... 
Via Benzinga
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and... 
Via Benzinga
Royal Pharma (RPRX) Q2 2021 Earnings Call Transcript
RPRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Royalty Pharma Q2 Earnings
Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year... 
Via Benzinga
Why MorphoSys Stock Sank This Week
Investors weren't happy about the drugmaker's wheeling and dealing. 
Via The Motley Fool
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... 
Via Benzinga
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
Royalty Pharma Insights: Return On Capital Employed
Royalty Pharma (NASDAQ:RPRX) posted a 26.99% decrease in earnings from Q4. Sales, however, increased by 0.18% over the previous quarter to $573.03 million. Despite the increase in... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.